Absci (ABSI) Revenue (2020 - 2026)

Absci (ABSI) posted Revenue of $215000.0 for Q1 2026, down 66.92% sequentially from $650000.0 in Q4 2025, and down 81.76% YoY from $1.2 million in Q1 2025.

Absci (ABSI) Revenue (2020 - 2026) Analysis & Trends

Absci has reported Revenue for 7 years, with the latest figure at $215000.0 in Q1 2026.

  • Quarterly Revenue fell 81.76% year-over-year to $215000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 61.87% YoY) and the FY2025 annual result came in at $2.8 million, down 38.24% from the prior year.
  • Revenue fell to $215000.0 in Q1 2026 per ABSI's latest filing, from $650000.0 in the prior quarter.
  • Over five years, Revenue peaked at $3.4 million in Q2 2023 and troughed at $215000.0 in Q1 2026.
  • A 5-year average of $902235.3 and a median of $665000.0 in 2024 frame the typical range for Revenue.
  • The sharpest annual moves came in 2023 and 2026: Revenue soared 247.67% in 2023, then tumbled 81.76% in 2026.
  • Over 5 years, Revenue stood at $339000.0 in 2022, then declined by 0.29% to $338000.0 in 2023, then soared by 96.75% to $665000.0 in 2024, then decreased by 2.26% to $650000.0 in 2025, then sank by 66.92% to $215000.0 in 2026.
  • According to Business Quant data, Revenue over the past three periods registered $215000.0, $650000.0, and $378000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1.56 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.71 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 3,001.92
7 Royalty Pharma 33.72 Bn 35.84 Bn - 674.14 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 1.29 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 425.49 Mn
10 Absci 1.58 Bn 1.37 Bn - 318,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 318,000.00
Mar 31, 2026 215,000.00
Dec 31, 2025 650,000.00
Sep 30, 2025 378,000.00
Jun 30, 2025 593,000.00
Mar 31, 2025 1.18 Mn
Dec 31, 2024 665,000.00
Sep 30, 2024 1.70 Mn
Jun 30, 2024 1.27 Mn
Mar 31, 2024 898,000.00
Dec 31, 2023 338,000.00
Sep 30, 2023 744,000.00
Jun 30, 2023 3.37 Mn
Mar 31, 2023 1.27 Mn
Dec 31, 2022 339,000.00
Sep 30, 2022 365,000.00
Jun 30, 2022 1.00 Mn
Mar 31, 2022 365,000.00
Dec 31, 2021 -2.15 Mn
Sep 30, 2021 149,000.00